These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 34175720

  • 1. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
    El-Adl K, Sakr HM, Yousef RG, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, Abulkhair HS, Eissa IH.
    Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
    [Abstract] [Full Text] [Related]

  • 2. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
    Eissa IH, El-Helby AA, Mahdy HA, Khalifa MM, Elnagar HA, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, El-Adl K.
    Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
    [Abstract] [Full Text] [Related]

  • 3. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA, Sakr H, Ayyad RRA, El-Adl K, Ali MM, Khedr F.
    Anticancer Agents Med Chem; 2018 Dec; 18(8):1184-1196. PubMed ID: 29651967
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
    Alsaif NA, Dahab MA, Alanazi MM, Obaidullah AJ, Al-Mehizia AA, Alanazi MM, Aldawas S, Mahdy HA, Elkady H.
    Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
    [Abstract] [Full Text] [Related]

  • 6. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
    El-Metwally SA, Abou-El-Regal MM, Eissa IH, Mehany ABM, Mahdy HA, Elkady H, Elwan A, Elkaeed EB.
    Bioorg Chem; 2021 Jul; 112():104947. PubMed ID: 33964580
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM, El-Gaby MSA, El-Adl K, Abd El-Sattar NEA.
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
    El-Adl K, El-Helby AA, Sakr H, El-Hddad SSA.
    Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis, and anti-proliferative evaluation of new quinazolin-4(3H)-ones as potential VEGFR-2 inhibitors.
    El-Adl K, El-Helby AA, Ayyad RR, Mahdy HA, Khalifa MM, Elnagar HA, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, Eissa IH.
    Bioorg Med Chem; 2021 Jan 01; 29():115872. PubMed ID: 33214036
    [Abstract] [Full Text] [Related]

  • 12. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
    El-Adl K, Ibrahim MK, Khedr F, Abulkhair HS, Eissa IH.
    Arch Pharm (Weinheim); 2021 Mar 01; 354(3):e2000219. PubMed ID: 33197080
    [Abstract] [Full Text] [Related]

  • 13. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA, Naglah AM, Moustafa GO, Awad HM, El Kerdawy AM.
    Bioorg Med Chem Lett; 2022 Feb 15; 58():128529. PubMed ID: 35007724
    [Abstract] [Full Text] [Related]

  • 14. Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers.
    Alsaif NA, Taghour MS, Alanazi MM, Obaidullah AJ, Al-Mehizia AA, Alanazi MM, Aldawas S, Elwan A, Elkady H.
    J Enzyme Inhib Med Chem; 2021 Dec 15; 36(1):1093-1114. PubMed ID: 34056992
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
    Sayed AM, Taher FA, Abdel-Samad MRK, El-Gaby MSA, El-Adl K, Saleh NM.
    Bioorg Chem; 2021 Mar 15; 108():104669. PubMed ID: 33515863
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies.
    Alanazi MM, Alaa E, Alsaif NA, Obaidullah AJ, Alkahtani HM, Al-Mehizia AA, Alsubaie SM, Taghour MS, Eissa IH.
    J Enzyme Inhib Med Chem; 2021 Dec 15; 36(1):1732-1750. PubMed ID: 34325596
    [Abstract] [Full Text] [Related]

  • 18. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study.
    El Hamaky NFM, Hamdi A, Bayoumi WA, Elgazar AA, Nasr MNA.
    Bioorg Chem; 2024 Jul 15; 148():107437. PubMed ID: 38749114
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K, Sakr H, El-Hddad SSA, El-Helby AA, Nasser M, Abulkhair HS.
    Arch Pharm (Weinheim); 2021 Jul 15; 354(7):e2000491. PubMed ID: 33788290
    [Abstract] [Full Text] [Related]

  • 20. Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors.
    Abdallah AE, Mabrouk RR, Al Ward MMS, Eissa SI, Elkaeed EB, Mehany ABM, Abo-Saif MA, El-Feky OA, Alesawy MS, El-Zahabi MA.
    J Enzyme Inhib Med Chem; 2022 Dec 15; 37(1):573-591. PubMed ID: 35012403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.